Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul:105:103703.
doi: 10.1016/j.drugpo.2022.103703. Epub 2022 May 10.

'Red Flags' and 'Red Tape': Telehealth and pharmacy-level barriers to buprenorphine in the United States

Lauren Textor  1 , Daniel Ventricelli  2 , Shoshana V Aronowitz  3
Affiliations

'Red Flags' and 'Red Tape': Telehealth and pharmacy-level barriers to buprenorphine in the United States

Lauren Textor et al. Int J Drug Policy. 2022 Jul.

Abstract

Background: Structural vulnerabilities for people who use drugs (PWUD) were exacerbated by the COVID-19 pandemic. In this context, federal lawmakers in the United States (U.S.) invoked an exemption to the 2008 Ryan Haight Act requiring in-person evaluation to prescribe buprenorphine for treatment of opioid use disorder (OUD), which allowed for the initiation and maintenance of buprenorphine via telehealth. Despite the potential for telehealth to address some of the geographic disparities in OUD treatment access, recent research has suggested that significant barriers to buprenorphine also exist at the pharmacy level. The purpose of this study was to qualitatively assess how efforts to increase access to buprenorphine via telehealth are implemented by prescribers and pharmacists and experienced by patients.

Methods: Participant observation and semi-structured interviews focused on telehealth for OUD treatment and buprenorphine prescribing and dispensing were conducted with patients (n = 19), prescribers and clinic staff (n = 24), and pharmacists (n = 10) in Pennsylvania and California between May 2020 - May 2021.

Findings: While participants stated that telehealth for OUD treatment was a welcome option, pharmacy-level barriers to buprenorphine persisted. Geographical distance from patient to provider or pharmacist continued to serve as "red flags" for pharmacists, leading to pharmacy-level "red tape:" gatekeeping measures including geographic restrictions, telephone prescription "confirmations," prescription cancellations and refusals. Patients' unmet expectations of buprenorphine access in some cases led to unanticipated risks including a return to injection drug use.

Conclusion: Challenges to increasing buprenorphine access persist in the U.S. even in settings where telehealth is implemented, and telehealth may inadvertently produce new barriers for some patients. Despite national support for policies aimed at increasing access to treatment for substance use disorders rather than punishment, policy shifts from punishment to treatment have not permeated evenly across all geographic areas and populations. Perceived threats of Drug Enforcement Administration (DEA) enforcement, and self-defensive institutional practices in pharmacies, reinforce ideologies of drug law enforcement, leading to poor patient outcomes including lack of buprenorphine access.

Keywords: Barriers; Drug policy; Opioid use disorder; Pharmacy; Telehealth.

PubMed Disclaimer

Conflict of interest statement

Declarations of Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

    1. Accusation Against OMAC Pharmacy and Robert Valusek. (2017). Bd. of Pharmacy Case No. 5371. Los Angeles. https://www.pharmacy.ca.gov/enforcement/fy1415/ac145371_rph55766.
    1. Ahmad FB, Rossen LM, & Sutton P. (2021). Provisional drug overdose death counts . https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm.
    1. Alexander M. (2010). The new Jim Crow: Mass incarceration in the age of colorblindness . New York: The New Press.
    1. Andrilla CHA, Moore TE, Patterson DG, & Larson EH (2019). Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update: Distribution of providers with a DEA waiver. The Journal of Rural Health: Official Journal of the American Rural Health Association and the National Rural Health Care Association, 35 (1), 108–112. 10.1111/jrh.12307. - DOI - PubMed
    1. Baillargeon J, Polychronopoulou E, Kuo Y−F, & Raji MA. (2021). The impact of substance use disorder on COVID-19 outcomes. Psychiatric Services, 72 (5), 578–581. 10.1176/appi.ps.202000534. - DOI - PMC - PubMed